Does the FDA recommend HRT for menopause

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, the FDA does recommend hormone therapy for menopause, but only for specific purposes: treating moderate to severe hot flashes, preventing bone loss, and treating genitourinary syndrome of menopause. According to the FDA-approved prescribing information for menopausal hormone therapy products, the FDA recommends using the lowest effective dose for the shortest amount of time that still gives good symptom relief. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

What the FDA Officially Says

According to FDA.gov, menopausal hormone therapy (estrogen with or without progesterone) is approved for three situations:

• Hot flashes and night sweats: According to FDA.gov, systemic estrogen is considered the most effective commercially available treatment when symptoms are moderate to severe.
• Bones: According to FDA.gov, estrogen may help prevent bone loss after menopause, and is viewed as an option when other bone medications are not suitable.
• Vaginal and urinary symptoms: According to the FDA-approved prescribing information, local estrogen (creams, rings, tablets) is approved for dryness, pain with intercourse, and urinary discomfort.

According to FDA.gov, hormone therapy is not recommended for preventing heart disease, improving memory, or for anti-aging purposes. Regulatory review has not demonstrated benefit in those areas, and FDA boxed warnings specifically note cardiovascular risks including stroke, deep vein thrombosis, and pulmonary embolism.

What "Lowest Dose for the Shortest Time" Really Means

• Lowest dose: According to FDA.gov, treatment should begin with a small amount of estrogen, increased only if symptoms remain significant. This reduces unnecessary exposure.
• Shortest time: According to FDA.gov, this does not mean rushing off therapy — it means staying on it only as long as symptoms meaningfully interfere with quality of life.
• Individualized decisions: According to FDA.gov, duration is not fixed; a qualified prescriber may continue therapy longer when benefits clearly outweigh the risks for an individual patient.

Why the FDA Takes This Approach

According to the FDA-approved prescribing information, estrogen may be effective for the approved indications, but it carries risks including blood clots and, for women with a uterus, a higher risk of uterine cancer if estrogen is used without progesterone. The FDA's guidance is designed to keep treatment appropriate while still allowing patients to obtain meaningful symptom relief when warranted. A qualified prescriber should assess individual risk factors before initiating or continuing hormone therapy.

In summary, according to FDA.gov, hormone therapy for menopause is recommended when symptoms are significant, and the FDA supports individualized, carefully monitored use under the guidance of a qualified prescriber.